1. Home
  2. Directory
  3. Wisconsin
  4. Oshkosh
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1619957230

STEPHEN J MERFELD M.D.
Prescription History 1619957230
Ophthalmology in Oshkosh, WI


Quality Rating: 100 out of 100 score

NPI Status: Active since January 19, 2006

Contact Information

1885 W POINTE DR
OSHKOSH, WI
ZIP 54902
Phone: (920) 232-6550
Fax: (920) 232-6552

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for STEPHEN J MERFELD M.D., an active Ophthalmology specialist practicing in Oshkosh, WI. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 235 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 116 claims alone.

Medication Index

B
D
L
T
No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 24
30-Day Fills 35.1
Days Supply 992
WI State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills100.0
Peer Average Days Supply2,894
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $281.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.75

State Avg Cost Per Claim

$39.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 62
30-Day Fills 103.4
Days Supply 2,992
WI State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills168.9
Peer Average Days Supply5,053
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,273.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.66

State Avg Cost Per Claim

$30.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 116
30-Day Fills 204.4
Days Supply 5,883
WI State Average Benchmarks
Peer Average Claims138.0
Peer Average 30-Day Fills266.6
Peer Average Days Supply7,688
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,642.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.78

State Avg Cost Per Claim

$26.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 13
30-Day Fills 16.5
Days Supply 460
WI State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills80.6
Peer Average Days Supply2,313
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.7% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,616.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$278.21

State Avg Cost Per Claim

$444.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Travoprost

Generic Formulation: TravoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 20
30-Day Fills 47.7
Days Supply 1,398
WI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills61.8
Peer Average Days Supply1,775
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,302.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$265.11

State Avg Cost Per Claim

$202.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like STEPHEN J MERFELD M.D. provides transparency into local medical care patterns within Oshkosh, WI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.